All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2022-06-06.
From the record
Solid Biosciences Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2022-06-06) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
7 filed years; profitable in 0 of 7.
From the record
Solid Biosciences Inc.'s 7 filed years say what it did: it rose in 0 of 1 years; the deepest fall was 41% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Solid Biosciences Inc.'s shareholder treatment is put at 1.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 13% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -97%: lost 97¢ per shareholder dollar. Leverage 23%: owes 23¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Solid Biosciences Inc. lost about 97 cents for every dollar of shareholders' money. Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count grew 114.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 34% of 102 in its family; net margin -1062.3%.
From the record
Solid Biosciences Inc.'s standing among 102 graded names in its industry family: revenue of $8 million in fiscal 2022 ranks in the bottom 35% by size; a net margin of -1062.3% ranks in the bottom 34% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 23% of 110 in its family for leadership; chief executive since 2022.
From the record
Solid Biosciences Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Cumbo, Alexander (President and CEO, as filed), filing under that title since the record of its people begins (2022-12-02), so the years before are not on the record and this part is not read; the 17 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 35%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (top 12%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 5.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Solid Biosciences Inc.'s room to expand is put at 5.0 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 50% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
top 50% of 100 in its family for growth drivers.
From the record
Solid Biosciences Inc.'s growth drivers, from the filed years to fiscal 2022: the newest year grew -40.6% (bottom 16%); research spending grew 21.4% a year (top 17%); capital spending grew -27.4% a year (top 47%) (its annual reports). Solid Biosciences Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 4.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Solid Biosciences Inc.'s expectations vs reality is put at 4.8 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 48% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made